Stempeutics Research
Bangalore, India· Est.
India‑based MSC biotech delivering approved cell‑therapy products and a growing pipeline of regenerative medicines.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
India‑based MSC biotech delivering approved cell‑therapy products and a growing pipeline of regenerative medicines.
Regenerative MedicineCell TherapyOrthopedicsVascular MedicineDermatology
Technology Platform
Proprietary pooled allogeneic MSC platform that combines bone‑marrow‑derived cells from multiple donors to create a standardized, off‑the‑shelf cell therapy with enhanced immunomodulatory and trophic properties.
Opportunities
Expansion of Stempeucel® into global markets and additional indications, leveraging its off‑the‑shelf MSC platform to meet rising demand for cost‑effective regenerative therapies.
Risk Factors
Regulatory hurdles in new territories, competition from other MSC developers, and the need to scale GMP manufacturing while preserving product consistency.
Competitive Landscape
Key competitors include Mesoblast, Pluristem, and TiGenix; Stempeutics differentiates through its pooled MSC approach, Indian regulatory approvals, and integrated cosmetic line.